Cell line · CVCL_0041
Papers75
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 75
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Circulating free and low-density lipoprotein-bound GD2 can compete in vitro with neuroblastoma cells for binding therapeutic anti-GD2 antibodies. | J Circ Biomark | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-Risk Rhabdomyosarcomas Feature a Convergent Cell State. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic targeting of YOD1 disrupts the PAX-FOXO1/N-Myc feedback loop in rhabdomyosarcoma. | JCI Insight | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PAX3-FOXO1 Drives Targetable Cell State-Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 40777370 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. | Genome Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| GEFT inhibits the GSDM-mediated proptosis signalling pathway, promoting the progression and drug resistance of rhabdomyosarcoma. | Cell Death Dis | 2024 | Its Methods give the RRID and name the line | PubMed | |
| SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0041/papers